Concepts (57)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Xerostomia | 4 | 2019 | 29 | 0.570 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2009 | 30 | 0.560 |
Why?
|
| Radiation Injuries | 3 | 2019 | 67 | 0.510 |
Why?
|
| Cranial Irradiation | 2 | 2019 | 84 | 0.330 |
Why?
|
| Ethmoid Sinus | 1 | 2005 | 1 | 0.280 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2005 | 2 | 0.270 |
Why?
|
| Nose Neoplasms | 1 | 2005 | 4 | 0.270 |
Why?
|
| Ear, Middle | 1 | 2005 | 8 | 0.260 |
Why?
|
| Ear, Inner | 1 | 2005 | 9 | 0.260 |
Why?
|
| Radiation Oncology | 1 | 2005 | 10 | 0.260 |
Why?
|
| Parotid Gland | 2 | 2019 | 6 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2004 | 337 | 0.260 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2005 | 28 | 0.260 |
Why?
|
| Prostatectomy | 2 | 2004 | 79 | 0.260 |
Why?
|
| Head and Neck Neoplasms | 2 | 2009 | 117 | 0.260 |
Why?
|
| Radiation Dosage | 2 | 2019 | 72 | 0.230 |
Why?
|
| Brain Neoplasms | 2 | 2019 | 587 | 0.230 |
Why?
|
| Prostatic Neoplasms | 2 | 2004 | 441 | 0.220 |
Why?
|
| Radiotherapy Dosage | 4 | 2019 | 98 | 0.200 |
Why?
|
| Dry Eye Syndromes | 1 | 2019 | 3 | 0.180 |
Why?
|
| Lacrimal Apparatus | 1 | 2019 | 6 | 0.180 |
Why?
|
| Salivation | 1 | 2019 | 5 | 0.170 |
Why?
|
| Radiotherapy, Conformal | 1 | 2019 | 19 | 0.170 |
Why?
|
| Salvage Therapy | 2 | 2004 | 118 | 0.120 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2009 | 4 | 0.090 |
Why?
|
| Humans | 8 | 2019 | 29123 | 0.090 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2009 | 15 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2009 | 436 | 0.080 |
Why?
|
| Adult | 5 | 2019 | 8426 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 2 | 2004 | 61 | 0.080 |
Why?
|
| Aged | 5 | 2019 | 9492 | 0.080 |
Why?
|
| Time Factors | 2 | 2019 | 2001 | 0.070 |
Why?
|
| Young Adult | 3 | 2019 | 2402 | 0.070 |
Why?
|
| Prognosis | 2 | 2009 | 1362 | 0.060 |
Why?
|
| Reference Values | 1 | 2005 | 224 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 68 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2005 | 263 | 0.060 |
Why?
|
| Postoperative Period | 1 | 2004 | 91 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2019 | 2021 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 637 | 0.060 |
Why?
|
| Male | 5 | 2019 | 17815 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 3719 | 0.050 |
Why?
|
| Middle Aged | 4 | 2019 | 10834 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 2109 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2004 | 3112 | 0.050 |
Why?
|
| Quality of Life | 1 | 2005 | 816 | 0.050 |
Why?
|
| Female | 3 | 2019 | 18173 | 0.030 |
Why?
|
| North Carolina | 1 | 2019 | 1423 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 1219 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 1306 | 0.030 |
Why?
|
| Risk Factors | 1 | 2019 | 3537 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 142 | 0.020 |
Why?
|
| Survivors | 1 | 2009 | 145 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2004 | 440 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 709 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2009 | 3101 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 3255 | 0.010 |
Why?
|